Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Oncolytics signs LOQTORZI supply deal for planned anal cancer study

Summary by themarketonline.ca
Oncolytics Biotech signed a clinical supply agreement with Coherus to test pelareorep with LOQTORZI in anal cancer, starting Q1 2027.

4 Articles

Cambridge TimesCambridge Times
+2 Reposted by 2 other sources
Lean Left

Oncolytics Biotech® Announces Clinical Supply Agreement to Evaluate Pelareorep in Combination with LOQTORZI® (toripalimab-tpzi) in Squamous Cell Anal Carcinoma

Pelareorep and toripalimab combine potentially complementary mechanisms designed to enhance antitumor immune responses and help overcome tumor immune resistance

·Cambridge, Canada
Read Full Article
themarketonline.cathemarketonline.ca

Oncolytics signs LOQTORZI supply deal for planned anal cancer study

Oncolytics Biotech signed a clinical supply agreement with Coherus to test pelareorep with LOQTORZI in anal cancer, starting Q1 2027.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources lean Left
100% Left

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Cambridge Times broke the news in Cambridge, Canada on Wednesday, November 11, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

Cancer icon

Cancer

Hamilton, Ontario icon

Hamilton, Ontario

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal